Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82242 | 0.89 | POLB (0.41) | NPC1RAB9AMAPTPOLBHTT | |
| SCHEMBL86826 | 0.87 | NPC1 (0.40) | NPC1RAB9APOLBHTTF2 | |
| SCHEMBL86593 | 0.87 | POLB (0.39) | NPC1RAB9APOLBHTTF2 | |
| SCHEMBL6261185 | 0.87 | MAPT (0.35) | NPC1RAB9AMAPTPOLBHTT | |
| SCHEMBL86948 | 0.85 | KMT2A (0.43) | NPC1RAB9AMAPTPOLBHTT | |
| SCHEMBL81415 | 0.83 | MAPT (0.47) | NPC1RAB9AMAPTPOLBHTT | |
| SCHEMBL86899 | 0.79 | HDAC3 (0.45) | NPC1RAB9AMAPTPOLBHTT | |
| SCHEMBL82578 | 0.79 | KDM4E (0.42) | NPC1RAB9AMAPTPOLBHTT | |
| SCHEMBL87263 | 0.79 | KMT2A (0.42) | NPC1RAB9AMAPTPOLBHTT | |
| SCHEMBL82997 | 0.78 | POLB (0.47) | NPC1RAB9AMAPTPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | claimed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | claimed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | claimed |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | BAYER CONSUMER CARE AG (CH) | 2021-11-30 | — | — | US | disclosed |
| EP-3843743-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | Bayer AS (NO) | 2021-07-07 | — | — | EP | disclosed |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2021-06-24 | — | — | US | disclosed |
| US-10925880-B2 | Combination of PI3K-inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| WO-2020164997-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-20 | — | — | WO | disclosed |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | BAYER CONSUMER CARE AG (CH) | 2020-07-16 | — | — | US | disclosed |
| WO-2020043617-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2020-03-05 | — | — | WO | disclosed |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-22 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | PIK3CA, PIK3CD, PIK3CB | NPC1 1925/4885RAB9A 1545/4885MAPT 844/4885 |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | AR, PIK3CA, AKT3 | NPC1 1214/4885RAB9A 935/4885MAPT 557/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | NPC1 3989/4885RAB9A 1944/4885MAPT 1939/4885 |
| US-10925880-B2 | Combination of PI3K-inhibitors | BCL9L, BCL9, MALT1 | NPC1 1109/4885RAB9A 1636/4885MAPT 4487/4885 |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BCL9L, BCL9, MALT1 | NPC1 1109/4885RAB9A 1636/4885MAPT 4487/4885 |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | AR, GSK3B, PIK3CA | NPC1 1320/4885RAB9A 793/4885MAPT 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.